文献速递肝病

Saroglitazar(PPAR-α/γ激动剂)治疗NAFLD:随机对照双盲2期试验

Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
PubMed 文献 · Hepatology · 2021-07-19

该随机对照双盲2期试验纳入106例ALT≥50 U/L且BMI≥25 kg/m2的NAFLD/NASH患者,按1:1:1:1随机接受安慰剂或saroglitazar 1 mg、2 mg、4 mg治疗16周。主要终点为第16周ALT较基线百分比变化,saroglitazar各剂量组均显著优于安慰剂(P<0.001)。4 mg组还显著改善肝脂肪含量、脂联素、胰岛素抵抗指数和甘油三酯(P<0.05)。

要点

  • Saroglitazar 4 mg治疗16周显著降低NAFLD/NASH患者ALT水平。
  • 4 mg组显著改善肝脂肪含量、胰岛素抵抗和致动脉粥样硬化性血脂异常。
  • 药物耐受性良好,4 mg组平均体重增加1.5 kg vs 安慰剂0.3 kg(P=0.27)。

核心结论

  • Saroglitazar 4 mg可显著改善NAFLD/NASH患者的ALT、肝脂肪含量、胰岛素抵抗和致动脉粥样硬化性血脂异常。

研究设计与样本

  • 随机对照双盲2期试验,纳入106例基线ALT≥50 U/L且BMI≥25 kg/m2的NAFLD/NASH患者,按1:1:1:1随机接受安慰剂或saroglitazar 1 mg、2 mg、4 mg治疗16周。

主要发现

  • 第16周ALT较基线最小二乘均值百分比变化:saroglitazar 1 mg组-25.5%(5.8)、2 mg组-27.7%(5.9)、4 mg组-45.8%(5.7),安慰剂组3.4%(5.6),所有剂量组P<0.001。
  • 与安慰剂相比,saroglitazar 4 mg改善肝脂肪含量(4.1% [5.9] vs -19.7% [5.6])、脂联素(-0.3 μg/mL [0.3] vs 1.3 μg/mL [0.3])、HOMA-IR(-1.3 [1.8] vs -6.3 [1.7])和甘油三酯(-5.3 mg/dL [10.7] vs -68.7 mg/dL [10.3]),所有P<0.05。
  • Saroglitazar 4 mg还改善脂蛋白颗粒组成和大小并减少脂毒性脂质种类。
  • Saroglitazar耐受性良好;4 mg组平均体重增加1.5 kg vs 安慰剂0.3 kg(P=0.27)。

临床怎么用

  • 对于NAFLD/NASH且ALT≥50 U/L、BMI≥25 kg/m2的患者,saroglitazar 4 mg治疗16周可显著改善ALT和肝脂肪含量。
  • 该药同时改善胰岛素抵抗和致动脉粥样硬化性血脂异常,可能对代谢综合征组分有多重获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: NAFLD is characterized by insulin resistance and dysregulated lipid and glucose metabolism. Saroglitazar, a dual peroxisome proliferator activated receptor-α/γ agonist, improves insulin sensitivity, and lipid and glycemic parameters. Saroglitazar improved NASH histology in animal studies. In this randomized controlled clinical trial, we evaluated the efficacy and safety of saroglitazar in patients with NAFLD/NASH. APPROACH AND RESULTS: A total of 106 patients with NAFLD/NASH with alanine aminotransferase (ALT) ≥ 50 U/L at baseline and body mass index ≥25 kg/m2 were randomized in a 1:1:1:1 ratio to receive placebo or saroglitazar 1 mg, 2 mg, or 4 mg for 16 weeks. The primary efficacy endpoint was percentage change from baseline in ALT levels at week 16. Liver fat content (LFC) was assessed by MRI proton density fat fraction. The least-squares mean percent change from baseline in ALT at week 16 was -25.5% (5.8), -27.7% (5.9), and -45.8% (5.7), with saroglitazar 1 mg, 2 mg, and 4 mg, respectively, versus 3.4% (5.6) in placebo (P < 0.001 for all). Compared with placebo, saroglitazar 4 mg improved LFC (4.1% [5.9] vs. -19.7% [5.6]), adiponectin (-0.3 μg/mL [0.3] vs. 1.3 μg/mL [0.3]), homeostatic model assessment-insulin resistance (-1.3 [1.8] vs. -6.3 [1.7]), and triglycerides (-5.3 mg/dL [10.7] vs. -68.7 mg/dL [10.3]) (P < 0.05 for all). Saroglitazar 4 mg also improved lipoprotein particle composition and size and reduced lipotoxic lipid species. Saroglitazar was well-tolerated. A mean weight gain of 1.5 kg was observed with saroglitazar 4 mg versus 0.3 kg with placebo (P = 0.27). CONCLUSIONS: Saroglitazar 4 mg significantly improved ALT, LFC, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. (ClinicalTrials.gov identifier: NCT03061721.).

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Gawrieh S, Noureddin M, Loo N, et al. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021. PMID: 33811367. doi:10.1002/hep.31843

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。